Clinical Trials Logo

Skin Neoplasms clinical trials

View clinical trials related to Skin Neoplasms.

Filter by:

NCT ID: NCT03693937 Completed - Clinical trials for Non-melanoma Skin Cancer

A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)

Start date: November 15, 2018
Phase:
Study type: Observational

Non-Melanoma Skin Cancer (NMSC) is the most commonly occurring type of skin cancer, and predominantly comprises (98%) Basal Cell Carcinomas (BCC) and Squamous Cell Carcinomas (SCC). About 3.3 million people in the United States (U.S.) are diagnosed with NMSC annually, equating about 5.4 million BCCs and SCCs. Low-dose Superficial Radiation Therapy (SRT) effectively destroys BCC and SCC without any invasive cutting, bleeding or stitching. There is no need for anesthesia, no risk of infection or scarring and no need for reconstructive plastic surgery. Healing time is quick with minimal to no post-treatment downtime or lifestyle restrictions. It is therefore both a viable and highly desirable alternative to invasive, painful and higher-risk surgical procedures. This study will utilize retrospective chart analysis to evaluate the outcomes of SRT-100™ therapy on NMSC lesions over a long-term post-treatment period.

NCT ID: NCT03677739 Recruiting - Clinical trials for Clinical Stage III Cutaneous Melanoma AJCC v8

Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families

Start date: June 3, 2019
Phase: N/A
Study type: Interventional

This trial studies how well Young Melanoma Family Facebook intervention or Healthy Lifestyle Facebook intervention works in improving skin examination in participants with melanoma and their families. Young Melanoma Family Facebook intervention or Healthy Lifestyle Facebook intervention may help improve total cutaneous examinations, skin self-examinations, and sun protection among first degree relatives of young onset participants and the participants themselves.

NCT ID: NCT03673917 Completed - Skin Cancer Clinical Trials

Cosmetology Students and Skin Cancer

Start date: September 15, 2016
Phase: N/A
Study type: Interventional

Assess the efficacy of training cosmetology students to detect suspicious skin lesions.

NCT ID: NCT03666325 Not yet recruiting - Skin Neoplasm Clinical Trials

Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance

I-Tackle
Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

Cutaneous Squamous Cell Cancer (Cscc, 25%) and basal cell carcinoma (BCC; 75%) are the major subtypes of non-melanoma skin cancer. Most cSCC arise in the head and neck region because it is frequently exposed to sunlight and its ensuing UV radiation-induced DNA damage, which is the major etiologic factor. There is an urgent need to identify new therapeutic targets for patients with locally advanced or metastatic squamous Cell Cancer of the skin. Substantial progress has recently been made in the development of immunotherapy for the treatment of cancer. In particular, the treatment with pembrolizumab alone or in conjunction with an anti epidermal growth factor receptor (EGFR) agent may reverse this condition, so performing radical surgery. Finally, the adjunct of an anti EGFR agent as cetuximab could reverse the primary and secondary resistance to pembrolizumab, with a synergistic effect able to counteract pathway redundancy (i.e. the presence of several concurrent pathways which need to be addressed together) and boosting T cell priming. Hence, there is rationale to combine cetuximab with pembrolizumab in order to increase its effectiveness.

NCT ID: NCT03655756 Completed - Clinical trials for Cutaneous Melanoma, Stage IV

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

Start date: November 5, 2018
Phase: Early Phase 1
Study type: Interventional

Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected). These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-7 business days for any delayed adverse events.

NCT ID: NCT03621462 Not yet recruiting - Melanoma (Skin) Clinical Trials

Elucid Labs AIDA™ - Labelled Image Acquisition Protocol

Start date: October 15, 2018
Phase: N/A
Study type: Interventional

Diagnosis of melanoma involves physical examination of the lesion with many dermatologists adjunctively employing dermoscopes. The rate of misdiagnosis of melanoma remains significant, along with a high rate of referral to biopsy. Elucid Labs (Waterloo, Ontario) has developed a novel handheld, digital dermoscope with accompanying visualization and analysis software - the Artificial Intelligence Dermatology Assistant (AIDA™). Apart from collecting conventional demoscopic images, AIDA also collects images at various spectral bands. The aim of this study is to understand and quantify the value of this novel adjunctive information for dermatologists diagnosing atypical skin lesions.

NCT ID: NCT03607578 Completed - Malignant Melanoma Clinical Trials

Test of Interventions to Prevent Skin Cancer Among Danes on Vacation in High UV Index Sunny Destinations

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

The aim of the study is to test a series of developed effective interventions targeting Danes going on vacation to sunny destinations to decrease sunburn by increasing use of shade, hats, protective clothing, and sunscreen to prevent skin cancer in the Danish population. It has been estimated that up to 90 % of all skin cancers could be avoided by behavioral changes. One of the main sources of UVR exposure in the Danish population is vacations to destinations with high UV index (UVI).

NCT ID: NCT03604666 Recruiting - Breast Cancer Clinical Trials

Follow-up of Elderly Patients in Ambulatory Surgery

PAPA
Start date: January 1, 2018
Phase:
Study type: Observational

The number of surgical procedures performed in ambulatory hospitalization for cancers of the skin or breast is increasing for medical and economic reasons. But the protocols of care and the clinical pathways are poorly adapted for elderly patients with physical or cognitive impairment. The goal of this study is to test the impact of an oncology ambulatory surgical care in patients aged 75 years or older, with breast or skin cancer and treated in Henri Mondor hospital on the increase in the proportion of patients operated on an outpatient basis

NCT ID: NCT03603587 Terminated - Skin Cancer Clinical Trials

Bioclinical Study of Scalp Photoaging of a Population Male Over 65 Years Old.

BACCHUS
Start date: February 14, 2019
Phase: N/A
Study type: Interventional

The aging of skin, especially that of the scalp, is a combination of intrinsic and extrinsic aging factors secondary to the chronic sun exposure. For men with an alopecia genetic (= bald men), the solar part, in skin aging process, is major. The helio-dermal scalp is frequently the site of cancers mainly after 65 years. Objectives are to identify specific biomarkers involved in the photo-aging of the alopecic scalp

NCT ID: NCT03590054 Completed - Metastatic Melanoma Clinical Trials

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Start date: August 20, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to other places in the body. Abexinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving abexinostat and pembrolizumab may work better in treating participants with solid tumors.